Download PDF
Thromb Haemost 1998; 80(05): 735-742
DOI: 10.1055/s-0037-1615351
Review Article
Schattauer GmbH

A Glanzmann Thrombasthenia-like Phenotype Caused by a Defect in Inside-Out Signaling through the Integrin αIIbβ3

Yoshiaki Tomiyama
1   From the Second Department of Internal Medicine, Osaka University Medical School
,
Masamichi Shiraga
1   From the Second Department of Internal Medicine, Osaka University Medical School
,
Seiji Kinoshita
3   From the Department of Pediatrics, Higashi Osaka Central Hospital, Osaka
,
Hironobu Ambo
4   From the Department of Internal Medicine, Keio University, Tokyo, Japan
,
Yoshiyuki Kurata
2   From the Department of Blood Transfusion, Osaka University Hospital, Osaka
,
Yuji Matsuzawa
1   From the Second Department of Internal Medicine, Osaka University Medical School
,
Thomas J. Kunicki
5   From the Departments of Molecular and Experimental Medicine and Vascular Biology, the Scripps Research Institute, La Jolla, CA, USA
› Author Affiliations
Further Information

Publication History

Received 13 January 1998

Accepted after revision 04 August 1998

Publication Date:
07 December 2017 (online)

    Permissions and Reprints

Summary

Activation of the platelet integrin αIIbβ3, an essential step in platelet aggregation, is regulated by intracellular signal pathways (inside-out signaling). In this study, we characterize a 35-year-old Japanese female, HM, with a life-long history of mucocutaneous bleeding. HM showed a Glanzmann thrombasthenia-like phenotype with normal expression of αIIbβ3, and failure of platelet aggregation induced by various agonists. An activation-independent ligand mimic monoclonal antibody (mAb), OP-G2, and RGDS peptides bound normally to the patient‘s αIIbβ3„ while an activating anti-β3 mAb, AP5, induced normal aggregation of HM platelets. The nucleotide sequence of the entire coding region of the patient‘s αIIb and β3, including the cytoplasmic domains of each subunit, revealed no abnormalities. Agonist-induced phosphorylation of platelet pleckstrin and myosin light chain was not impaired. Recently, we proposed that a Na+/Ca2+ exchanger is involved in inside-out signaling, especially in the case of chymotrypsin-induced αIIbβ3 activation (Blood 88: 2594, 1996). However, chymotrypsin-induced platelet aggregation occurred normally in patient HM. Measurement of changes in cytosolic free calcium concentration ([Ca2+]i) revealed that the plateau level of [Ca2+]i after thrombin stimulation was significantly inhibited in patient HM. Our data suggest that patient HM exhibits a Glanzmann thrombasthenia-like phenotype associated with an abnormality in inside-out signaling which would otherwise activate αIIbβ3.

 

  • References

  • 1 Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
    CrossrefPubMedGoogle Scholar
  • 2 Ruoslahti E. Integrins. J Clin Invest 1991; 87: 1-5.
    CrossrefPubMedGoogle Scholar
  • 3 Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988; 71: 831-43.
    PubMedGoogle Scholar
  • 4 Smyth SS, Joneckis CC, Parise LV. Regulation of vascular integrins. Blood 1993; 81: 2827-43.
    PubMedGoogle Scholar
  • 5 Faull RJ, Ginsberg MH. Dynamic regulation of integrins. Stem Cells 1995; 13: 38-46.
    CrossrefPubMedGoogle Scholar
  • 6 Frelinger AL III, Du X, Plow EF, Ginsberg MH. Monoclonal antibodies to ligand-occupied conformers of integrin αIIbβ3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function. J Biol Chem 1991; 266: 17106-11.
    PubMedGoogle Scholar
  • 7 Ginsberg MH, Frelinger AL, Lam SC-T, Forsyth J, McMillan R, Plow EF, Shattil SJ. Analysis of platelet aggregation disorders based on flow cyto-metric analysis of membrane glycoprotein IIb-IIIa with conformation-specific monoclonal antibodies. Blood 1990; 76: 2017-23.
    PubMedGoogle Scholar
  • 8 George JN, Caen JP, Nurden AT. Glanzmann‘s thrombasthenia: the spectrum of clinical disease. Blood 1990; 75: 1383-95.
    PubMedGoogle Scholar
  • 9 O’Toole TE, Katagiri Y, Faull RJ, Peter K, Tamura R, Quaranta V, Loftus JC, Shattil SJ, Ginsberg MH. Integrin cytoplasmic domains mediate inside-out signal transduction. J Cell Biol 1994; 124: 1047-59.
    CrossrefPubMedGoogle Scholar
  • 10 Du X, Gu M, Weisel JW, Nagaswami C, Bennett JS, Bowditch R, Ginsberg MH. Long range propagation of conformational changes in integrin αIIbβ3 . J Biol Chem 1993; 268: 23087-92.
    PubMedGoogle Scholar
  • 11 Kroll MH, Schafer AI. Biochemical mechanisms of platelet activation. Blood 1989; 74: 1181-95.
    PubMedGoogle Scholar
  • 12 Blockmans D, Deckmyn H, Vermylen J. Platelet activation. Blood Reviews 1995; 9: 143-56.
    CrossrefPubMedGoogle Scholar
  • 13 Shattil SJ. Function and regulation of the β3 integrins in hemostasis and vascular biology. Thromb Haemost 1995; 74: 149-55.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Bray PF. Inherited diseases of platelet glycoproteins: considerations for rapid molecular characterization. Thromb Haemost 1994; 72: 492-502.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Coller BS, Seligsohn U, Peretz H, Newman PJ. Glanzmann thrombasthenia: new insights from an historical perspective. Semin Hematol 1994; 31: 301-11.
    PubMedGoogle Scholar
  • 16 Loftus JC, O’Toole TE, Plow EF, Glass A, Frelinger AL III, Ginsberg MH. A β3 integrin mutation abolishes ligand binding and alters divalent cation-dependent conformation. Science 1990; 249: 915-8.
    CrossrefPubMedGoogle Scholar
  • 17 Bajt ML, Ginsberg MH, Frelinger AL III, Berndt MC, Loftus JC. A spontaneous mutation of integrin αIIbβ3 (platelet glycoprotein IIb-IIIa) helps define a ligand binding site. J Biol Chem 1992; 267: 3789-94.
    PubMedGoogle Scholar
  • 18 Lanza F, Stierlé A, Fournier D, Morales M, André G, Nurden AT, Cazenave J-P. A new variant of Glanzmann‘s thrombasthenia (Strasbourg I): platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg → 214Trp mutation. J Clin Invest 1992; 89: 1995-2004.
    CrossrefPubMedGoogle Scholar
  • 19 Honda S, Tomiyama Y, Shiraga M, Tadokoro S, Takamatsu J, Saito H, Kurata Y, Matsuzawa Y. A two-amino acid insertion in the Cys146-Cys167 loop of the aIIb subunit is associated with a variant of Glanzmann thrombasthenia: critical role of Asp163 in ligand binding. J Clin Invest 1998; 102: 1183-92.
    CrossrefPubMedGoogle Scholar
  • 20 Chen Y-P, Djaffar I, Pidard D, Steiner B, Cieutat A-M, Caen JP, Rosa J-P. Ser-752 R Pro mutation in the cytoplasmic domain of integrin β3 subunit and defective activation of platelet integrin αIIbβ3 (glycoprotein IIb-IIIa) in a variant of Glanzmann thrombasthenia. Proc Natl Acad Sci USA 1992; 89: 10169-73.
    CrossrefPubMedGoogle Scholar
  • 21 Tomiyama Y, Kashiwagi H, Kosugi S, Shiraga M, Kinoshita S, Kanayama Y, Kurata Y, Matsuzawa Y. Demonstration of a marked reduction in the amount of GPIIb in most type II patients with Glanzmann‘s thrombasthenia. Br J Haematol 1994; 87: 119-24.
    CrossrefPubMedGoogle Scholar
  • 22 Tomiyama Y, Tsubakio T, Piotrowicz RS, Kurata Y, Loftus JC, Kunicki TJ. The Arg-Gly-Asp (RGD) recognition site of platelet glycoprotein IIb-IIIa on nonactivated platelets is accessible to high-affinity macromolecules. Blood 1992; 79: 2303-12.
    PubMedGoogle Scholar
  • 23 Pidard D, Montgomery RR, Bennett JS, Kunicki TJ. Interaction of AP2, a monoclonal antibody specific for the human platelet glycoprotein IIb-IIIa complex, with intact platelets. J Biol Chem 1983; 258: 12582-6.
    PubMedGoogle Scholar
  • 24 Tomiyama Y, Brojer E, Ruggeri ZM, Shattil SJ, Smiltneck J, Gorski J, Kumar A, Kieber-Emmons T, Kunicki TJ. A molecular model of RGD ligands: antibody D gene segments that direct specificity for the integrin αIIbβ3 . J Biol Chem 1992; 267: 18085-92.
    PubMedGoogle Scholar
  • 25 Bajt ML, Loftus JC. Mutation of a ligand binding domain of β3 integrin: integral role of oxygenated residues in αIIbβ3 (GPIIb-IIIa) receptor function. J Biol Chem 1994; 269: 20913-9.
    PubMedGoogle Scholar
  • 26 Honda S, Tomiyama Y, Pelletier AJ, Annis D, Honda Y, Orchekowski R, Ruggeri Z, Kunicki TJ. Topography of ligand-induced binding sites, including a novel cation-sensitive epitope (AP5) at the amino terminus, of the human integrin β3 subunit. J Biol Chem 1995; 270: 11947-54.
    CrossrefPubMedGoogle Scholar
  • 27 Loftus JC, Plow EF, Frelinger AL III, D’Souza SE, Dixon D, Lacy J, Sorge J, Ginsberg MH. Molecular cloning and chemical synthesis of a region of platelet glycoprotein IIb involved in adhesive function. Proc Natl Acad Sci USA 1987; 84: 7114-8.
    CrossrefPubMedGoogle Scholar
  • 28 Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985; 101: 880-6.
    CrossrefPubMedGoogle Scholar
  • 29 Shiraga M, Tomiyama Y, Honda S, Kashiwagi H, Kosugi S, Handa M, Ikeda Y, Kanakura Y, Kurata Y, Matsuzawa Y. Affinity modulation of the platelet integrinαIIbβ3 by a-chymotrypsin: a possible role for Na+/Ca2+ exchanger. Blood 1996; 88: 2594-602.
    PubMedGoogle Scholar
  • 30 Tomiyama Y, Kurata Y, Mizutani H, Kanakura Y, Tsubakio T, Yonezawa T, Tarui S. Platelet glycoprotein IIb as a target antigen in two patients with chronic idiopathic thrombocytopenic purpura. Br J Haematol 1987; 66: 535-8.
    CrossrefPubMedGoogle Scholar
  • 31 Shiraga M, Tomiyama Y, Honda S, Suzuki H, Kosugi S, Tadokoro S, Kanakura Y, Tanoue K, Kurata Y. Matsuzawa Y: Involvement of Na+/Ca2+ exchanger in inside-out signaling through the platelet integrin αIIbβ3 . Blood. 1998 resubmission, in press.
    PubMedGoogle Scholar
  • 32 Tomiyama Y, Kashiwagi H, Kosugi S, Shiraga M, Kanayama Y, Kurata Y, Matsuzawa Y. Abnormal processing of the glycoprotein IIb transcript due to a nonsense mutation in exon 17 associated with Glanzmann‘s thrombasthenia. Thromb Haemost 1995; 73: 756-62.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Tadokoro S, Tomiyama Y, Honda S, Arai M, Yamamoto N, Shiraga M, Kosugi S, Kanakura Y, Kurata Y, Matsuzawa Y. A Gln → Pro substitution in the αIIb subunit is responsible for a moderate αIIbβ3 deficiency in Glanz-mann thrombasthenia. Blood. 1998 in press.
    PubMedGoogle Scholar
  • 34 Tanoue K, Hasegawa S, Yamaguchi A, Yamamoto N, Yamazaki H. A new variant of thrombasthenia with abnormally glycosylated GPIIb/IIIa. Thromb Research 1987; 47: 323-33.
    CrossrefPubMedGoogle Scholar
  • 35 Wang R, McFarland JG, Kekomaki R, Newman PJ. Amino Acid 489 is encoded by a mutational “hot spot” on the β3 integrin chain:the CA/TU human platelet alloantigen system. Blood 1993; 82: 3386-91.
    PubMedGoogle Scholar
  • 36 Niessner H, Clemetson KJ, Panzer S, Mueller-Eckhardt C, Santoso S, Bettelheim P. Acquired thrombasthenia due to GPIIb/IIIa-specific platelet autoantibodies. Blood 1986; 68: 571-6.
    PubMedGoogle Scholar
  • 37 Chen Y-P, O’Toole TE, Ylänne J, Rosa J-P, Ginsberg MH. A point mutation in the integrin β3 cytoplasmic domain (S752 → P) impairs bidirectional signaling through αIIbβ3 (platelet glycoprotein IIb-IIIa). Blood 1994; 84: 1857-65.
    PubMedGoogle Scholar
  • 38 Baker EK, Tozer EC, Pfaff M, Shattil S, Loftus JC, Ginsberg MH. A genetic analysis of integrin function: Glanzmann thrombasthenia in vitro. Proc Natl Acad Sci USA 1997; 94: 1973-8.
    CrossrefPubMedGoogle Scholar
  • 39 Shattil SJ, Brass LF. Induction of the fibrinogen receptor on human platelets by intracellular mediators. J Biol Chem 1987; 262: 992-1000.
    PubMedGoogle Scholar
  • 40 Pulcinelli FM, Ashby B, Gazzaniga PP, Daniel JL. Protein kinase C activation is not a key step in ADP-mediated exposure of fibrinogen receptors on human platelets. FEBS lett 1995; 364: 87-90.
    CrossrefPubMedGoogle Scholar
  • 41 Gabbeta J, Yang X, Sun L, McLane MA, Niewiarowski S, Rao AK. Abnormal inside-out signal transduction-dependent activation of glycoprotein IIb-IIIa in a patient with impaired pleckstrin phosphorylation. Blood 1996; 87: 1368-76.
    PubMedGoogle Scholar
  • 42 Kornecki E, Cooper BA, Ehrlich YH. Identification of a unique type of thrombopathy of human platelets: defect in the exposure of active fibrinogen receptors in a patient with Friedreich‘s ataxia. J Lab Clin Med 1988; 111: 618-26.
    PubMedGoogle Scholar
  • 43 Shattil SJ, O’Toole T, Eigenthaler M, Thon V, Williams M, Babior BM, Ginsberg MH. β3-endonexin, a novel polypeptide that interacts specifically with the cytoplasmic tail of the integrin β3 subunit. J Cell Biol 1995; 131: 807-16.
    CrossrefPubMedGoogle Scholar
  • 44 Kashiwagi H, Schwartz MA, Eigenthaler M, Davis KA, Ginsberg MH, Shattil SJ. Affinity modulation of platelet integrin αIIbβ3 by β3-endonexin, a selective binding partner of the β3 integrin cytoplasmic tail. J Cell Biol 1997; 137: 1433-43.
    CrossrefPubMedGoogle Scholar
  • 45 Zhang Z, Vuori K, Wang H-G, Reed JC, Ruoslahti E. Integrin activation by R-ras. Cell 1996; 85: 61-9.
    CrossrefPubMedGoogle Scholar
  • 46 Greenberg JP, Packham MA, Guccione MA, Harfenist EJ, Orr JL, Kinlough-Rathbone RL, Perry DW, Mustard LF. The effect of pretreatment of human or rabbit platelets with chymotrypsin on their responses to human fibrinogen and aggregating agents. Blood 1979; 54: 753-65.
    PubMedGoogle Scholar
  • 47 Niewiarowski S, Budzynski AZ, Morinelli TA, Brudzynski TM, Stewart GJ. Exposure of fibrinogen receptor on human platelets by proteolytic enzymes. J Biol Chem 1981; 256: 917-25.
    PubMedGoogle Scholar
  • 48 Rink TJ, Sage SO. Calcium signaling in human platelets. Annu Rev Physiol 1990; 52: 431-49.
    CrossrefPubMedGoogle Scholar
  • 49 Hashimoto Y, Ogihara A, Nakanishi S, Matsuda Y, Kurokawa K, Nonomura Y. Two thrombin-activated Ca2+ channels in human platelets. J Biol Chem 1992; 267: 17078-81.
    PubMedGoogle Scholar